🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Most viewed in the last 7 days from JAMA Cardiology: In patients with ST-segment elevation myocardial infarction, does prehospital pulse-dose glucocorticoid treatment have a cardioprotective effect? ja.ma/3ZcDclM

This debate explores the pros and cons of using percutaneous transvalvular microaxial flow pumps for patients with infarct-related cardiogenic shock. While the DanGer Shock trial showed a significant reduction in mortality using these pumps, concerns remain around complications

Results of the PULSE-MI trial show that in pts with STEMI, prehospital pulse-dose glucocorticoid did not reduce final infarct size after 3 mos. Patients treated with glucocorticoid had higher acute LVEF, reduced acute infarct size, & less MVO. ja.ma/4f4Mwge

Ugeskrift for læger har fokus på kardiologi 🫀🔊 Vi har skrevet et indlæg om akutte kardiologiske tilstande, hvor hurtig udredning og behandling er vigtigt 🚑 Det er vigtigt, at vi tænker de akutte sygdomme med når sundhedsvæsenet skal udvikle sig 🏨 tinyurl.com/233ukhxs

Substudy of DanGer Shock trial: microaxial flow pump reduced need for vasoactive drugs while maintaining hemodynamic stability & achieving faster normalization of lactate levels in pts w/ cardiogenic shock after ST-elevation myocardial infarction. #TCT2024 ja.ma/3Adk5Oy

Ouch, QFR. In the FAVOR III Europe trial, it loses out against FFR for PCI guidance. For those who enjoy statistical tortures, QFR didn’t just fail to show noninferiority; it was actually inferior. More stents, more myocardial infarctions. Who will give me back the hours I spent

Just out 📢 In patients with diabetes and STEMI💉🫀, GLP-1RA treatment prior to STEMI admission was associated with significantly lower ⬇️ long-term mortality🩺! @JasmineMMadsen Thomas Engstrøm doi.org/10.1186/s12933…

In patients with diabetes and ST-segment elevation myocardial infarction (STEMI), glucagon-like peptide-1 receptor agonist treatment prior to STEMI admission is associated with lower long-term mortality, reports a study in Cardiovascular Diabetology. cardiab.biomedcentral.com/articles/10.11…

🤔Could microvascular resistance explain the acute beneficial effects of #prehospital pulse dose glucocorticoids in #STEMI patients?💔 💡We tried to answer this exact question in our recently published #substudy of the #PULSEMI trial ⬇️ link.springer.com/article/10.118…

Watching from home! 🚀#EuroPCR RigsHeart 🫀🚨

#EuroPCR #JACC LBCT: #FFR-guided complete #revascularization reduced future and repeated events compared with infarct-related artery only after 10 years. The risk was mainly driven by revasc, with no reduction in MIs or death. jacc.org/doi/10.1016/j.… #cvMI Jasmine Melissa Marquard

Is deferring immediate stenting in #STEMI of benefit? 10-Year Outcomes of Deferred or Conventional Stent Implantation in Patients with STEMI. The DANAMI-3-DEFER Study presented PCRonline 🫀 #EuroPCR and published simultaneously EuroIntervention #AHAJournals ahajournals.org/doi/full/10.11…

DANGER-shock substudy just presented by at #EuroPCR shows lower mortality in STEMI-CS patients with multi vessel disease treated with immediate multi-vessel PCI 🧐 RigsHeart 🫀🚨

Just presented from the DANAMI-3 Primulti trial #EuroPCR showing the benefit of regarding long term outcome of multi-vessel PCI in STEMI-patients RigsHeart 🫀🚨 JACC Journals

Immediate Multivessel PCI May Not Be So Bad in STEMI Patients With Shock: DanGer Data tctmd.com/news/immediate…

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI tctmd.com/news/complete-…

ahajournals.org/doi/10.1161/CI…

jacc.org/doi/10.1016/j.…